Want to see IT:DIA full AI Analyst Report?
Top Page
DiaSorin S.p.A.
(DIA)
Select Model
Select Model
Rating:66Neutral
Price Target:
€72.00
▲(7.88% Upside)
Action:Reiterated
Date:07/09/26
The score is primarily supported by strong cash flow generation and solid operating margins, alongside an improving leverage profile. Offsetting factors are a softer recent top-line trend and net margin compression versus prior peaks, while technical indicators are neutral and valuation (P/E ~26.6) is only partly supported by the ~2% dividend yield.
Positive Factors
Recurring consumables revenue
DiaSorin’s business model ties instruments to repeat reagent and assay sales, producing predictable, utilization‑based revenue from installed systems. This durable revenue annuity supports stable cash flow, higher lifetime customer value, and more predictable planning over 2–6 months.
Negative Factors
Softening top-line growth
A recent TTM revenue decline suggests slower demand or lower test volumes, which can impede expansion of the installed base and reduce future consumable consumption. Unless revenue growth stabilizes, recurring revenue cadence and long‑term growth potential may be constrained.
Read all positive and negative factors
Positive Factors
Negative Factors
Recurring consumables revenue
DiaSorin’s business model ties instruments to repeat reagent and assay sales, producing predictable, utilization‑based revenue from installed systems. This durable revenue annuity supports stable cash flow, higher lifetime customer value, and more predictable planning over 2–6 months.
Read all positive factors
DiaSorin S.p.A. (DIA) vs. iShares MSCI Italy ETF (EWI)
Market Cap
€3.88B
Dividend Yield1.81%
Average Volume (3M)221.33K
Price to Earnings (P/E)22.4
Beta (1Y)0.25
Revenue Growth-3.10%
EPS Growth-27.86%
CountryIT
Employees3,242
SectorGeneral
Sector StrengthN/A
IndustryMedical - Diagnostics & Research
Share Statistics
EPS (TTM)2.59
Shares Outstanding55,948,257
10 Day Avg. Volume225,158
30 Day Avg. Volume221,334
Financial Highlights & Ratios
PEG Ratio-1.37
Price to Book (P/B)2.42
Price to Sales (P/S)3.21
P/FCF Ratio18.72
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€67.22Price Target Upside0.71% Upside
Rating ConsensusHold
Number of Analyst Covering6
EPS Forecast (FY)3.97
Revenue Forecast (FY)€1.23B
DiaSorin S.p.A. Business Overview & Revenue Model
Company Description
DiaSorin S.p.A. engages in research and development, manufacture, and distribution of immunodiagnostics and molecular diagnostics testing kits in Europe, North America, and internationally. It provides various immunodiagnostic in the areas, includ...
How the Company Makes Money
DiaSorin primarily makes money by selling in-vitro diagnostic solutions that combine (1) diagnostic instruments and (2) recurring consumables used on those instruments. A significant portion of revenue is typically driven by repeat purchases of re...
DiaSorin S.p.A. Financial Statement Overview
Summary
Income Statement
72
Positive
Balance Sheet
70
Positive
Cash Flow
76
Positive
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 1.45B | 1.20B | 1.19B | 1.15B | 1.36B | 1.24B |
| Gross Profit | 937.00M | 699.89M | 781.00M | 741.19M | 900.61M | 824.77M |
| EBITDA | 408.62M | 432.81M | 399.04M | 333.40M | 479.71M | 504.56M |
| Net Income | 174.67M | 155.62M | 188.10M | 159.85M | 240.91M | 310.97M |
Balance Sheet | ||||||
| Total Assets | 2.47B | 2.87B | 3.30B | 3.21B | 3.41B | 3.23B |
| Cash, Cash Equivalents and Short-Term Investments | 0.00 | 211.65M | 378.92M | 403.39M | 413.22M | 403.02M |
| Total Debt | 711.00M | 791.16M | 1.01B | 1.19B | 1.35B | 1.40B |
| Total Liabilities | 972.00M | 1.30B | 1.51B | 1.67B | 1.89B | 1.86B |
| Stockholders Equity | 1.50B | 1.58B | 1.80B | 1.54B | 1.52B | 1.37B |
Cash Flow | ||||||
| Free Cash Flow | 383.03M | 205.08M | 239.07M | 266.20M | 275.65M | 283.29M |
| Operating Cash Flow | 444.76M | 342.76M | 358.78M | 311.66M | 389.34M | 400.66M |
| Investing Cash Flow | -216.52M | -144.52M | -49.81M | -29.10M | -231.95M | -1.61B |
| Financing Cash Flow | -392.18M | -351.18M | -259.13M | -235.96M | -333.04M | 1.26B |
DiaSorin S.p.A. Technical Analysis
Positive
66.74
Price Trends
68.23
Positive
65.01
Positive
66.32
Positive
Market Momentum
1.00
Negative
66.87
Neutral
83.80
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IT:DIA, the sentiment is Positive. The current price of 66.74 is below the 20-day moving average (MA) of 69.12, below the 50-day MA of 68.23, and above the 200-day MA of 66.32, indicating a bullish trend. The MACD of 1.00 indicates Negative momentum. The RSI at 66.87 is Neutral, neither overbought nor oversold. The STOCH value of 83.80 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for IT:DIA.
DiaSorin S.p.A. Peers Comparison
UnderperformOutperform
Sector (55)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
75 Outperform | €1.25B | 14.80 | 16.55% | 1.60% | 4.42% | -16.04% | |
75 Outperform | €10.66B | 21.26 | 24.25% | 2.61% | 9.10% | 22.99% | |
66 Neutral | €3.88B | 22.38 | 11.29% | 1.95% | -3.10% | -27.86% | |
60 Neutral | €3.28B | 41.72 | 6.80% | 2.63% | -0.48% | -47.11% | |
59 Neutral | €688.02M | 14.13 | 12.37% | ― | -0.99% | 118.45% | |
55 Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% | |
43 Neutral | €11.49M | -0.34 | 17.04% | ― | 74.59% | ― |
* General Sector Average
IT:DIA
DiaSorin S.p.A.
75.16
-8.55
-10.21%
IT:AMP
Amplifon S.p.A.
12.11
-2.56
-17.48%
IT:ELN
El.En. S.p.A.
15.78
3.89
32.73%
IT:FDA
Fidia Spa
0.01
-0.30
-96.72%
IT:REC
Recordati Industria Chimica e Farmaceutica SPA
51.65
2.56
5.22%
IT:SFL
Safilo Group SpA
1.69
0.43
33.81%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.